BrainsWay Posts Strong Q1 2026 Growth, Reiterates Full-Year Guidance
Event summary
- Revenue grew 35% year-over-year to $15.5 million in Q1 2026.
- Net income more than doubled to $2.3 million, up from $1.1 million in Q1 2025.
- Shipped a record 117 Deep TMS Systems, a 44% increase from Q1 2025.
- Remaining performance obligations (RPOs) increased 25% to $75 million.
- Reiterated full-year 2026 guidance with revenue expected between $66–$68 million.
The big picture
BrainsWay's strong Q1 2026 performance highlights the growing demand for its Deep TMS technology, driven by broader reimbursement and increasing provider adoption. The company's strategic investments and pipeline expansions position it to capitalize on the unmet needs in mental health disorders, particularly in underserved markets like PTSD and alcohol use disorder. However, sustaining this momentum will depend on regulatory approvals and maintaining its competitive edge in a rapidly evolving neurostimulation market.
What we're watching
- Regulatory Progress
- The pace at which BrainsWay secures insurer coverage for its SWIFT protocol and FDA approval for PTSD treatment in MDD patients will determine market access and revenue growth.
- Execution Risk
- Whether BrainsWay can sustain its 35% revenue growth rate and meet its full-year guidance amid increasing competition and reimbursement challenges.
- Strategic Investments
- How BrainsWay's investments in Neurolief, BrainStim Health Inc., and Axis Management Company will impact its long-term growth and diversification strategy.
Related topics